This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring

€500 savings end in:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
THE SPRINGTIME PARTNERING EVENT
March 18–20, 2024 | Barcelona, SpainMarch 26–27, 2024 | Digital Partnering

DiaMedica Therapeutics

Profile

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases. Its lead candidate is in a pivotal trail for stroke and stroke recurrence with DM199. DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality for the treatment of acute ischemic stroke, hypertension and chronic kidney disease. For more information visit the Company’s website at www.diamedica.com. DiaMedica recently initiate a pivotal Phase 2/3 for stoke recurrence and stroke recovery, study design with 2 independent primary endpoints. Also in Phase 2 for IgA Nephropathy and hypertensive African Americans with CKD. Stroke Recurrence and Stroke Recovery : In Phase 2, DM199 prevented acute ischemic stroke recurrence, 0% vs placebo 13% (P=0.01). Also improved stroke recoveries and reduced deaths by 12% vs placebo. The study drug (DM199 or placebo) was administered within 24 hours of stroke symptom onset, followed by 3 weeks treatment. DM199 was safe and well tolerated. DM199 is in a pivotal Phase 2/3 ReMEDy trial.